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Resumo 
 
A leucinose é uma doença autossómica recessiva que envolve o metabolismo dos 
aminoácidos ramificados (BCAAs) – leucina, isoleucina e valina – e cuja incidência na maioria 
das populações é de 1/185.000 recém-nascidos. Mutações num dos três genes- BCKDHA, 
BCKDHB e DBT – que codificam os componentes catalíticos E1α, E1β e E2, respetivamente, do 
complexo da desidrogenase dos α-cetoácidos ramificados (BCKD) podem causar leucinose.  
Neste trabalho, fez-se a caracterização molecular de 2 doentes recentemente 
diagnosticados com leucinose. Num deles, de origem angolana, foi detetada uma deleção de 11 
bp (c.93_103del11; p.Ala32Phefs*48) em homozigotia no gene BCKDHB, que já tinha sido 
anteriormente descrita. No outro paciente, de origem portuguesa, identificaram-se duas 
mutações em heterozigotia, c.799C>T (p.Gln267X) e c.359T>C (p.Phe120Ser), também no gene 
BCKDHB. Como a mutação c.359T>C nunca tinha sido descrita, para avaliar o seu possível efeito 
patogénico, usaram-se vários programas bioinformáticos e analisou-se o efeito da alteração na 
estrutura 3D da proteína, tendo sido obtido resultados consistentemente apontando para o efeito 
causal da mutação.  
Por outro lado, foi efetuada a análise funcional da mutação c.108+6T>C do gene 
BCKDHA. Esta alteração tinha sido detetada pela primeira vez num doente de origem brasileira 
também diagnosticado com leucinose. Tendo as análises preliminares in silico indicado que a 
alteração deveria muito provavelmente alterar o normal padrão de splicing do gene em que 
ocorria, no sentido de confirmar o efeito patogénico recorreu-se à construção de minigenes 
através da clonagem do exão 1 e parte do intrão 1 do gene BCKDHA, com e sem mutação, no 
vetor pSPL3. O estudo do minigene em células HeLA e AGS e posterior extração do RNA e 
síntese do cDNA possibilitou a análise dos transcritos processados. Pela comparação dos 
transcritos produzidos pelo minigene WT e pelo minigene com a mutação, concluiu-se que a 
mutação comprometia o processo de splicing da zona genómica em estudo, causando o skipping 
do exão clonado no vector pSPL3. Deste modo, afigura-se altamente expectável que in vivo a 
mutação c.108+6T>C faça com que o local de splicing onde se localiza deixe de ser reconhecido, 
causando o skipping do exão 1. 
Este trabalho veio enriquecer o conhecimento sobre o espectro mutacional da leucinose, 
uma vez que resultou na descrição de duas novas mutações, uma delas missense (c.359T>C; 
p.Phe120Ser em BCKDHB) e a outra de splicing (c.108+6T>C em BCKDHA). Para a última, foi 
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ainda possível confirmar a nível funcional o seu efeito ao nível do mRNA do gene BCKDHA, 
contribuindo para reforçar o papel da desregulação do splicing como agente responsável por 
doenças. 
O trabalho permitiu também demonstrar a eficácia da estratégia baseada na construção 
e clonagem de minigenes para avaliar o efeito de mutações suspeitas de afetar o splicing. O 
esforço agora desenvolvido para estabelecer adequadamente os procedimentos técnicos 
necessários, permitirá no futuro a utilização dos minigenes para investigar o efeito de outras 
mutações candidatas a interferir no processo de splicing.  
 
 
Palavras-chave: BCKDHA; BCKDHB; Leucinose; Minigene; Mutação de splicing. 
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Abstract 
 
Maple syrup urine disease (MSUD) is an autosomal recessive disease that affects the 
metabolism of branched-chain amino acids (BCAAs) – leucine, isoleucine and valine, whose 
incidence is about 1/185.000 live newborns in most populations. Mutations in any of the three 
different genes – BCKDHA, BCKDHB and DBT – encoding respectively for the E1α, E1β and E2 
catalytic components of the branched-chain α-ketoacid dehydrogenase (BCKD) complex can 
cause maple syrup urine disease (MSUD). 
In this study, the molecular characterization of two newly diagnosed patients with MSUD 
was conducted. In one of them, with Angolan origin, a previously described deletion of 11 bp 
(c.93_103del11; p.Ala32Phefs*48) was identified in homozygosity in BCKDHB gene. In the other 
patient, with Portuguese origin, two mutations in heterozygosity were identified also in BCKDHB, 
c.799C>T (p.Gln267X) and c.359T>C (p.Phe120Ser). The c.359T>C mutation had never been 
described and as so, to assess their possible pathogenic effect several bioinformatics programs 
were used as well as it was performed 3D structure analysis, obtaining results consistently 
pinpointing the disease causative effect of the mutation.  
Furthermore, the functional analysis of the substitution c.108+6T>C in intron 1 of BCKDHA 
previously identified in a patient from Brazil diagnosed with MSUD was also performed. Since 
preliminary in silico analyses had indicated that it probably induced an alteration in the normal 
splicing pattern of the gene, in order to confirm the previsions, a minigene system was constructed 
by cloning exon 1 and part of intron 1 of BCKDHA gene, with and without the substitution, in 
pSPL3 vector.  
The study of this minigene in HeLa and AGS cells and subsequent RNA extraction and 
cDNA synthesis allowed the analysis of the processed transcripts. Through the comparison of the 
transcripts produced by the WT minigene and by the mutant one, it was possible to conclude that 
the alteration indeed affected the splicing process in the gene since the presence of the 
c.108+6T>C mutation resulted in the skipping of the exon cloned into pSPL3 vector. Therefore, it 
seems very likely that in vivo the mutation causes the skipping of exon 1 of BCKDHA gene. 
This work contributed to increase the knowledge on the mutational spectrum of MSUD 
since it led to identify two new alterations, one missense mutation (c.359T>C; p.Phe120Ser in 
BCKDHB) and a splicing mutation (c.108+6T>C in BCKDHA). Concerning this latter, its 
pathogenic impact was in addition functionally demonstrated. 
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Furthermore, this work has evidenced the efficiency of a strategy based on the 
construction of minigene systems to evaluate the effect of a mutation of uncertain pathogenic 
impact on splicing. The efforts invested in the implementation of reliable methodologies, will allow 
in the future to extend the approach to other mutations that might interfere with splicing.  
 
 
Key-words: BCKDHA; BCKDHB; Maple Syrup Urine Disease; Minigene; Splicing mutation. 
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1. Introduction 
1.1. Branched-chain amino acids metabolism 
The branched-chain amino acids (BCAAs), leucine, isoleucine and valine, are neutral, 
aliphatic amino acids with a branched methyl group in the side chain. 
BCAAs are essential, also called indispensable, amino acids that need to be obtained from 
the diet in sufficient amounts to promote normal growth and development. Usually they comprise 
about 15%-20% of the total protein intake from food (Layman, 2003). BCAAs play important roles 
in cellular function, especially leucine since it promotes protein synthesis, inhibits protein 
degradation and stimulates insulin release (Mordier et al., 2000; Proud, 2002; Lynch et al., 2002). 
The first step in the catabolism of leucine, isoleucine and valine (Figure 1) is a reversible 
transamination catalyzed by branched-chain aminotransferase isozymes (BCATs), including a 
mitochondrial form with ubiquitous distribution and a cytosolic BCAT present mainly in the nervous 
system, to form their respective branched-chain α-ketoacids (BCKAs): α-ketoisocaproate (KIC), 
α-keto-β-methylvalerate (KMV) and α-ketoisovalerate (KIV) (Harper et al., 1984). The cytosolic 
BCKAs are then transported across the mitochondrial membrane (Hutson and Hall, 1993). Once 
in the mitochondria, branched-chain α-ketoacid dehydrogenase (BCKD) complex catalyzes the 
oxidative decarboxylation of BCKAs, generating their respective branched-chain acyl-CoAs, that 
are further metabolized via separate pathways (Figure 1) (Harris et al., 1997).  
The step catalyzed by BCKD commits the BCAAs to degradation, being so the rate-limiting 
step in the BCAA catabolism (Harris et al., 1990) (Chuang and Shih, 2001). The BCKD complex 
is therefore the most important regulatory enzyme in the catabolic pathway of the BCAAs (Harris 
et al., 2005). 
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Figure 1. BCAA catabolic pathways. The first step is transamination of the BCAAs (leucine (Leu), isoleucine (Ile), valine (Val) to 
produce the branched-chain α-keto acids (BCKAs): α-ketoisocaproate (KIC), α-keto-β-methylvalerate (KMV) and α-ketoisovalerate 
(KIV). α-ketoglutarate is the α-keto acid acceptor of the BCAA α-amino group and glutamate (Glu) is the product. The second catabolic 
step is oxidative decarboxylation, catalyzed by the branched chain α-keto acid dehydrogenase (BCKD) complex. Leucine is ketogenic, 
forming acetyl-CoA and acetoacetate, valine is glucogenic, entering the tricarboxylic acid (TCA) cycle as succinyl-CoA, whereas 
isoleucine is both ketogenic and glucogenic. Adapted by Hutson et al., 2005.  
 
1.2. Branched-chain α-ketoacid dehydrogenase complex 
The human branched-chain α-ketoacid dehydrogenase (BCKD) catalytic machine is a 
member of the highly conserved mitochondrial α-ketoacid dehydrogenase complexes comprising 
BCKD complex, pyruvate dehydrogenase complex (PDC) and α-ketoglutarate dehydrogenase 
complex (Reed et al., 1985). 
The BCKD complex is composed by three catalytic components - a decarboxylase (E1) 
that has a heterotetrameric structure formed by two E1α and two E1β subunits (α2β2), a 
dihydrolipoyl transacylase (E2) and a dihydrolipoamide dehydrogenase (E3). The complex has 
also two regulatory enzymes, which are a specific kinase (BCKDK) and a specific phosphatase 
(PP2Cm) (Yeaman, 1989) (Figure 2). 
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Components E1, E2 and the regulatory enzymes are specific of BCKD, while E3 is shared 
by the three α-ketoacid dehydrogenase complexes and by the glycine cleavage complex 
(Yeaman, 1989; Danner and Doering 1998).  
The complex is organized around a 24-meric cubic core of E2, to which 12 copies of E1, 
6 copies of E3, and the kinase and the phosphatase are attached (Yeaman, 1989; Danner and 
Doering 1998). 
BCKD complex requires several cofactors to function properly, including thiamine 
pyrophosphate (for the E1 component), coenzyme A (for the E2 component), lipoamide, flavin 
and nicotinamide adenine dinucleotides (FAD and NAD) for the E3 component.  
Activity of the complex is controlled by covalent modification through phosphorylation of a 
serine residue (Ser-337 previously identified as Ser-292) of the E1α subunit performed by the 
specific kinase of the complex that causes inactivation of the E1 component and consequently of 
the complex; dephosphorylation by the specific phosphatase leads to the reactivation of BCKD 
(Damuni et al., 1984; Popov et al., 1992). The extent to which the complex is dephosphorylated 
and therefore catalytically active depends on the relative activities of PP2Cm and BCKDK (Harris 
et al., 2001). At low BCAA levels, E1α is hyperphosphorylated by BCKD kinase, leading to lower 
BCKD activity and reduced loss of BCAA. At elevated BCAA levels, E1α is dephosphorylated by 
BCKD phosphatase, to induce BCKD complex activity and the removal of excess of BCAA. 
Therefore, BCKD phosphorylation/dephosphorylation is critical to BCAA homeostasis (Sun et al., 
2011).  
All components of BCKD complex are encoded by nuclear genes. The human E1α gene 
(BCKDHA) (MIM #608348) is located at chromosome 19 (19q13.1-13.2) and has 9 exons leading 
to an mRNA that is translated into a protein with 445 residues (Fekete et al., 1989). The BCKDHB 
gene (MIM #24861), which encodes the E1β protein, is located at the chromosome 6 (6q14.1) 
(Zneimer et al., 1991), has 11 exons and originates a protein with 392 residues (Edelmann et al., 
2001). The E2 protein is codified by the DBT gene (MIM #248610) that is located at the 
chromosome 1 (1p31). This gene is composed by 11 exons and originates a protein with 482 aa 
(Zneimer et al., 1991). DLD (MIM #238331) at chromosome 7 (7q31-32) encodes the E3 protein, 
and contains 14 exons forming a protein with 509 aa (Scherer et al., 1991). 
Concerning the regulatory subunits of BCKD complex, the gene for the specific BCKD kinase 
(BCKDK) is located on chromosome 16 at 16p11.2 and has 13 exons encoding a protein of 412 
residues (Suryawan et al., 1998). The gene for the BCKD specific phosphatase (PPM1K) is 
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located on chromosome 4 and consists of 7 exons that are translated into a protein with 372 
residues (Damuni et al., 1984) (Lu et al., 2009). 
Genetic defects leading to impairment of the BCKD complex are responsible for a 
condition known as Maple Syrup Urine Disease (MSUD) (Harris et al., 2004). 
 
 
Figure 2. Representation of the branched chain α-ketoacid dehydrogenase (BCKD) complex. Adapted from (Ævarsson  
et al., 2000). 
  
1.3. Maple Syrup Urine Disease 
Inherited metabolic diseases are caused by the deficiency or even absence of activity of 
a particular enzyme in a metabolic pathway. The blockage can lead to the accumulation of toxic 
substances in body fluids and tissues or lack of essential metabolites, many times leading to 
implications for the mental and/or physical development of affected individuals. The majority of 
these disorders is characterized by an autosomal recessive pattern of inheritance.  
Among them is maple syrup urine disease (MSUD; OMIM 248600), an autosomal 
recessive disorder, first described in 1954 by Menkes and collaborators (Menkes et al., 1954) that 
is associated to dysfunction of branched-chain amino acids metabolism. The characteristic odor 
of the urine of the patients, resembling maple syrup, gave the name to the disease (Dancis et al., 
1959). The metabolic block causing MSUD was then identified to occur in the decarboxylation of 
BCKAs, due to the deficient activity of BCKD complex (Dancis et al., 1960) (Menkes, 1959).   
 
1.3.1. Clinical phenotypes 
The classic form of MSUD is the most severe subtype with neonatal onset. Affected 
newborns have 0-2% of normal BCKD complex activity (Packman et al., 2012) and although 
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apparently healthy at birth the progressive accumulation of BCKAs and BCAAs conduct to the 
development of the symptoms in the first days of life. Patients present poor feeding and irritability 
that, if untreated, may progress to lethargy, coma and ultimately death. This subtype of MSUD 
has the highest morbidity and is the most common, accounting for about 75% of the patients 
(McLaughlin et al., 2013). 
Patients with the intermediate form have consistently abnormal BCAAs profile and 
neurologic deterioration, but do not develop catastrophic illness in the initial days of life as 
observed in classic MSUD. BCKD complex activity is usually higher than in the previous form, 
lying between 3 to 30% of normal. Most patients are diagnosed between five months and seven 
years of age (Chuang and Shih, 2001).  
Intermittent MSUD patients show normal early development, growth and intelligence but 
metabolic decompensation can occur as a result of any physiologic stress. In spite of that, when 
asymptomatic these individuals usually tolerate a regular diet and have normal levels of plasma 
BCAAs. Activity of the BCKD complex is reportedly 5 to 20% of normal, with the diagnosis usually 
being established between 5 months and 2 years of age. During acute crises, behavioral changes 
may progress to seizures and coma and at this time the biochemical profile is similar to that of 
classic MSUD (Chuang and Shih 2001). 
The thiamine-responsive form was first described by Scriver and collaborators (1971) in 
patients in whom the hyperaminoacidemia was completely corrected by administration of thiamine 
hydrochloride. As occurs in the intermediate type there is no neonatal illness and BCKD complex 
activity is about 30 to 40% of the normal rate (Chuang et al., 1982). Patients with this phenotype 
are usually treated with combined therapy of dietary adjusted restriction and thiamine 
supplementation. 
The E3-deficient type is associated with combined enzyme deficiencies in pyruvate 
dehydrogenase, α-ketoglutarate dehydrogenase and BCKD complexes because E3 is a common 
component among these mitochondrial α-ketoacid dehydrogenase complexes (Yeaman, 1989). 
Patients with this disease form present a severe phenotype distinct from MSUD that is 
characterized by lactic acidosis and progressive neurologic deterioration (Robinson et al., 1977).  
 
1.3.2. Diagnosis  
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In newborns or young children manifesting clinical symptoms suggestive of MSUD, 
diagnosis confirmation is performed through amino acid and organic acid analysis profile, by 
measuring the plasma BCAAs concentrations that are usually elevated five to ten-fold greater 
than normal and by detection of  alloisoleucine that has been considered as a pathognomonic 
marker for the confirmation of the diagnosis (Snyderman et al., 1964; Strauss and Morton, 2003; 
Chuang et al., 2006). A general disturbance of amino acid concentration ratios is also observed 
(Chuang and Shih, 2001, Morton et al., 2002) and high levels of the BCKAs derived from the 
BCAAs can also be detected in the urine. 
However, in the last decades the identification or suspicion of MSUD patients become 
possible even before the manifestation of the first symptoms since the disease has been included 
in the expanded newborn screening programs already implemented in many countries, including 
Portugal (Vilarinho et al., 2006). For the screening, it is used tandem mass spectrometry (MS/MS) 
whose results permits to identify newborn suspects who may develop MSUD in the first days of 
life, therefore allowing immediate therapeutic implementation. The inclusion of MSUD in the 
MS/MS newborn screening program represents a major improvement since early diagnosis and 
intervention during the pre-symptomatic or early symptomatic period improves the outcome of the 
patients and usually prevents irreversible brain damage (Schadewaldt et al., 1999; Simon et al., 
2006).  
In patients with positive results in the neonatal screening, the biochemical diagnosis 
(previously described) must be performed to confirm the diagnosis.  
Whenever possible, the deficiency of the branched-chain α-ketoacid dehydrogenase 
enzyme complex activity may also be measured in cultured fibroblasts or lymphocytes as an 
additional method for diagnosis confirmation. 
Molecular diagnostic allows the identification of causative mutations, which is crucial to 
provide prenatal diagnosis in high-risk pregnancies and carrier detection in family members to 
offer them genetic counseling. 
 
1.3.3. Treatments 
As for the majority of metabolic diseases, therapy for MSUD comprises long-term disease-
specific approaches that consists mainly in dietary restriction of the amino acids that cannot be 
properly degraded, particularly of leucine, and replacement of deficient substrates, which in the 
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case of MSUD was firstly proposed by Snyderman (Snyderman et al., 1964). Besides, emergency 
treatments are usually implemented during metabolic decompensation crisis. 
Since the intellectual outcome of patients is dependent on the time that leucine levels 
remain above the normal, to protect the neonatal brain of the acutely ill newborn from permanent 
damage an emergency treatment is used to reduce leucine concentration as rapidly as possible. 
This intervention consists mainly in exogenous toxin removal, because a high-energy enteral or 
parenteral nutrition alone is insufficiently effective to rapidly lower plasma leucine levels (Berry et 
al., 1991). For metabolic removal in acute situations, peritoneal dialysis or venous hemofiltration 
can be performed while high calorie fluids are provided intravenously to inhibit catabolism and 
promote anabolism. 
Besides this emergency intervention, long term dietary therapy is also used in MSUD 
patients during all life to normalize the concentration of blood BCAAs and to provide adequate 
nutrition to promote normal growth and development, especially in young patients. This treatment 
consists fundamentally in a BCAA-restricted diet that should be adjusted to each patient individual 
requirements viewing which BCAAs levels must be regularly monitored. Thiamine 
supplementation should be used to test for thiamine-responsiveness of the patients. Several 
commercial synthetic formulas are already available for MSUD patients, which are enriched with 
the amino acids that compete with BCAA transport and help to maintain physiological amino acid 
plasma levels and transport into the brain (Strauss et al., 2010).  
In asymptomatic individuals with mild variant forms of MSUD the necessity of long-term 
treatment is yet unclear, but interventions such as prevention of metabolic crisis, careful 
instructions of affected families and evaluation to identify individuals at risk for metabolic 
decompensation are recommended (Vockley et al., 2006; Simon et al., 2006).  
Interestingly, liver transplantation has been suggested as an effective treatment for classic 
MSUD. This discovery was made from the observation of various patients with MSUD who 
required liver transplantation for liver failure and demonstrated a positive metabolic outcome 
(Strauss et al., 2006; Diaz et al., 2014). Since then, numerous liver transplants have been 
performed and the effectiveness of this procedure in MSUD suggests that providing 9-13% of the 
bodies’ BCKD complex activity is sufficient to restore BCKD complex homeostasis (Burrage et 
al., 2014). However, liver transplantation has important risks, such as postoperative complications 
and the need for long-term immunosuppression, which must be carefully evaluated and 
considered. 
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1.3.4. Incidence and mutational spectrum  
MSUD is a rare disorder, affecting around 1/185.000 live births, thought it can attain very 
high incidence in populations or communities where endogamous practices are common (Chuang 
and Shih 2001). That is the case of some Old Order Mennonite communities, where a high 
incidence of classic MSUD is observed due to the alteration p.Tyr438Asn in E1α (Marshall and 
DiGeorge, 1981; Zhang et al., 1989) or the p.Arg183Pro in E1β, affecting the Ashkenazy Jewish 
(Edelmann et al., 2001). In Portugal, MSUD has been estimated to affect 1/86.800 live newborns, 
which represents an incidence slightly higher than reported in most populations, but that can be 
mainly explained by the presence of a founder mutation (c.117delC in BCKDHA) in a Gypsy 
community from the South of the country (Quental et al., 2008). 
MSUD is mainly caused by recessively inherited mutations in any of the three genes that 
code for catalytic subunits specific of the BCKD complex namely BCKDHA (E1α), BCKDHB (E1β) 
and DBT (E2). Recently, however, a patient with a mild variant phenotype was reported to have 
a mutation in the BCKD specific phosphatase (PP2Cm, PPM1K gene) (Oyarzabal et al., 2013). 
A comprehensive knowledge of the MSUD mutational spectrum has important implications 
for disease management and genetic counseling (Narayanan et al., 2013). 
Up to now, more than 150 pathogenic alterations underlying MSUD have been identified, 
distributed in a near equal number in the three genes that encode the catalytic subunits (Quental, 
2009).  
According to the data available in the Human Gene Mutation Database (version 2013.4; 
http://www.hgmd.org/), the majority of the alterations that cause MSUD comprises single 
nucleotide substitutions (~74%),  including the commonly referred “splicing mutations”, which are 
those that disrupt the normal splicing or alternative splicing of gene’ transcripts. In the last years, 
much attention has been given to the mechanisms by which disruption of pre-mRNA splicing play 
a role in human disease, being increasingly acknowledged that the understanding of the 
pathobiology of splicing expands opportunities for therapeutic intervention by either directly 
addressing the cause or by providing novel approaches to circumvent disease processes (Ward 
and Cooper, 2010). 
 
1.4. Splicing process 
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Expression of eukaryotic structural genes is a multistep process that includes transcription 
of the gene, splicing and polyadenylation of the primary transcript, and transport of the fully 
processed mRNA to the cytoplasm (Singer and Green, 1997).  
Most genes in higher eukaryotes are transcribed as precursor mRNAs (pre-mRNAs) that 
contain intervening sequences (introns) as well as expressed sequences (exons). The process of 
pre-mRNA splicing, discovered in the late 1970s, briefly consists in a series of reactions whereby 
the intronic RNA segments are removed and discarded while the remaining exonic segments are 
joined end-to-end, to give a shorter RNA product (Strachan T. and Read A. (2010) Human 
Molecular Genetics, 4th edition) .The precision and complexity of intron removal during pre-mRNA 
splicing still amazes even several years after its discovery. 
The spliceosome is the macromolecular machine that performs the two primary functions 
of splicing: recognition of the intron/exon boundaries and catalysis of the cut-and-paste reactions 
that remove introns and join exons (Faustino and Cooper, 2003). It is a dynamic ribonucleoprotein 
complex composed by five small nuclear ribonucleoproteins (snRNPs) (U1, U2, U4, U5 and U6), 
each of which contains an RNA known as a snRNA and an elevated number of other non-snRNP 
proteins (Matera and Wang, 2014).  
For an efficient splicing process, both cis-regulatory sequences and trans-acting factors 
are needed. The cis elements include highly conserved sequences such as donor and acceptor 
sites positioned at exon-intron boundaries, the branch point and the polypyrimidine tract, as well 
as auxiliary elements, that include exonic and intronic splicing enhancers (ESEs and ISEs, 
respectively) and silencers (ESS and ISSs, respectively) (Figure 3). Trans-acting elements may 
be divided into spliceosome and splicing factors which intervene through binding to splicing 
enhancers and silencers and include members of the well-characterized Ser/Arg-rich and 
heterogeneous nuclear ribonucleoprotein (hnRNP) protein families (Kornblihtt et al., 2013). 
The specificity of the splicing reaction is established by RNA-RNA base pairing between 
the RNA transcript to be spliced and snRNA molecules within the spliceosome. 
First, U1 binds to the 5’ splice site, while U2 binds the intron branch site via RNA:RNA 
interactions between the snRNA and the pre-mRNA. Interaction between the splice donor and 
splice acceptor sites is stabilized by the binding of a multi-snRNP particle that contains the U4, 
U5 and U6 snRNAs. The U5 snRNP binds simultaneously to both the splice donor and splice 
acceptor sites. Their cleavage releases the intronic sequence and allows both exons to be spliced 
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together (Figure 4) (Faustino and Cooper, 2003); (Strachan T. and Read A. (2010) Human 
Molecular Genetics, 4th edition). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Exonic and intronic elements (Cooper, 2005) 
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Figure 4. A simplified view of the spliceosome and process of splicing. Splicing involves several RNA-protein complexes, called small 
nuclear ribonucleoproteins (snRNPs), which together make up the spliceosome. U1 snRNP binds to the boundary between exon 1 
and the intron by recognizing a specific sequence. U2 snRNP subsequently binds to the branch site (A) and then U4/U5/U6 triple 
snRNPs join in. After a dynamic rearrangement, U1 and U4 are destabilized, and the remaining snRNP complex is activated for the 
two steps that remove the intron and stitch together exons 1 and 2 (Gottlieb, 2003).  
 
  
1.5. Alternative splicing  
 Through the process of alternative splicing (AS), different combinations of exons to use in 
the final mRNA transcript can be generated, creating different isoforms of a single gene (Douglas 
and Wood, 2011), and as so AS is considered one major source of protein diversity explaining 
the immense mammalian proteomic complexity. In fact, more than 90% of human genes undergo 
alternative splicing (Luco et al., 2011).  
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Almost all protein-coding genes contain introns that are removed in the nucleus by RNA 
splicing during pre-mRNA processing but, as mentioned, exon usage is often alternative because 
a part of pre-mRNA can be removed as an intron or included in the mature mRNA as an alternative 
exon (Ben-Dov et al., 2008). The relative positions of weak and strong splice sites give rise to the 
different modes of alternative splicing including: inclusion of alternative cassette exons that can 
be independently included or excluded from the mRNA (Figure 5.A); inclusion of alternative 
mutually exclusive cassette exons (Figure 5.B); use of alternative 5’ splice sites or alternative 3’ 
splice sites (Figure 5.C and 5.D); retention of alternative introns (Figure 5.E) and alternative 
splicing in conjunction with the use of alternative promoters (Figure 5.F) or poly(A) sites 
alternatives (Figure 5.G) (Matlin et al., 2005); (Kornblihtt et al., 2013). 
 
 
Figure 5. Different modes of alternative splicing. Adapted from (Matlin et al., 2005). 
 
1.6. Splicing and disease  
 
Since splicing is a major regulatory step in gene expression, any alteration of the splicing 
pattern of one or multiple transcripts can disrupt the production or function(s) of the encoded 
protein(s) leading to a wide range of phenotypic consequences. 
Actually, splicing mutations account for approximately 10% of roughly 80,000 mutations 
associated to inherited diseases contained in the human gene mutation database (2014).  In 
2003, Faustino and Cooper have classified this type of disease causing alterations into four 
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categories: cis-acting mutations, those that disrupt the use of constitutive splice sites; cis-acting 
mutations, when they disrupt the use of alternative splice sites; trans-acting mutations, if 
compromising the basal splicing machinery and trans-acting mutations, when disturbing splicing 
regulation.  
Cis-acting mutations that affect the use of constitutive splice sites most of the times result 
in loss of gene expression due to nonsense-mediated decay (NMD) or expression of proteins 
containing internal deletions, a shift in the reading frame, or C-terminal truncations. In fact, the 
most commonly detected splicing mutations are located at conserved donor (5’) and acceptor (3’) 
splice sites while mutations in the branch site or in the polypyrimidine tract are rare 
(Lewandowska, 2013). Furthermore, alteration in ESE, ESS, ISE, or ISS have also been 
recognized as a cause of genetic disease through splicing alteration (Baralle and Baralle, 2005). 
This type of mutations frequently result in exon skipping, use of nearby cryptic 5´or 3´splice site, 
or even in retention of the mutated intron. Alternative splice sites can also be mutated and, in this 
case, a mutation that inactivates one of the alternatively used splice sites will force expression of 
the alternative splicing patterns.  
Trans-acting splicing mutations, in its turn, can affect the function of the basal splicing 
machinery or factors that regulate alternative splicing. Mutations that affect the basal splicing 
machinery have the potential to affect splicing of all pre-mRNAs, whereas mutations that affect a 
regulator of alternative splicing will affect only the subset of pre-mRNAs that are targets of the 
regulator (Faustino and Cooper, 2003).  
 The more that is known about RNA splicing, the more is recognized its relevance in terms 
of health and disease. In figure 6, are illustrated examples of different splicing events and their 
consequences at protein level. 
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Figure 6. Examples of different splicing events and their consequences at protein level due to changes in pre-mRNA expression that 
can cause disease. In the process of splicing can happen the removal of exons or retention of introns resulting in the formation of 
different mature mRNA transcripts for the same gene. Different mature mRNA transcripts encode for different proteins  (Faiz and 
Burgess, 2012).  
 
 
1.7. Use of minigenes to study splicing mutations  
 
In recent years, the development of high throughput technologies allowed the detection of 
many changes in intronic sequences and intron/exon boundaries.  
The assessment of whether a mutation affects exon recognition and results in a genetic 
disorder is, however, not always simple. Direct analysis of the processed transcripts from the 
patients is the most reliable method to confirm that a specific alteration affects splicing and should 
therefore be the method of choice to investigate the consequences of a splicing mutation. 
Unfortunately, in many cases it is not possible to perform such analysis as for example, when is 
not available, a sample from the patient, or from the appropriate tissue when the mutation affects 
tissue specific gene expression, suitable to extract RNA (Baralle et al., 2009). To overcome these 
circumstances, the establishment of a causal effect of a mutation can rely on the use of molecular 
biology methods such as in vitro transcription of the sequence of interest cloned into a plasmid, 
with and without alterations, or hybrid minigene systems to perform mutation analysis 
(Lewandowska, 2013).  
FCUP 
Contribution to the mutational spectrum of Maple Syrup Urine Disease                                                                           
and functional characterization of the alteration c.108+6T>C in BCKDHA gene. 
41 
 
 
Minigene constructs (Figure 7) have revealed to be an important tool for the identification 
and in vivo analysis of the cis-acting regulatory elements and trans-acting factors that establish 
splicing efficiency and that regulate alternative splicing. Expression of minigene pre-mRNAs by 
transient transfection provides a rapid assay to perform loss or gain of function analyses of factors 
that affect splicing regulation and therefore can be used to address a number of different 
questions with regard to alternative splicing and splicing mutations (Cooper, 2005). 
When the aim is to study a putative splicing mutation, the minigene should contain a 
genomic segment from the gene of interest that includes the site of the alteration, usually the exon 
and part of the flanking introns. This fragment, which will be cloned into splicing vector, is amplified 
from genomic DNA (from normal and affected individuals) using oligonucleotides containing 
restriction enzyme sites at their 5’ ends that match restriction sites in the recipient plasmid, being 
most convenient to select two restriction enzymes that cut efficiently in the same buffer to obtain 
more efficient and reliable reaction (Gaildrat et al., 2010). Alternatively, the mutant minigene can 
also be constructed through site directed mutagenesis of the control/normal one. 
Once constructed, the minigenes are transfected into the appropriate cultured cells where 
RNA undergoes splicing. The comparison of the splicing patterns, through RT-PCR using vector 
specific primers, of the transcripts generated from the wild-type and from the mutant minigenes, 
affords evidence on the functional effect of the alteration. The main strengths of the minigene 
approach are the abilities to demonstrate that specific nucleotide changes affect splicing efficiency 
and to define elements required for responsiveness to cell type and specific splicing regulators 
(Cooper, 2005) (Perez et al., 2013). 
Many studies have already been undertaken in which minigenes were used to understand 
and assess the impact of splicing alterations. For example, in 2010 the strategy was applied by 
Fernández-Guerra and collaborators to demonstrate the pathogenic impact of 
an intronic mutation in BCKDHA gene causing a variant form of MSUD (Fernández-Guerra et al., 
2010).  
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Figure 7. Representative scheme of the construction of a minigene in a plasmid vector. CMV – cytomegalovirus transcriptional 
enhancer/promoter. RS #1 and RS#2 – restriction sites located on the plasmid. The genomic fragment to be cloned into the minigene 
is amplified from genomic DNA using oligonucleotides containing restriction enzyme sites at their 5’ ends that match restriction sites 
in the plasmid. These sites depend on the available cloning sites within the minigene (RS#1 and RS#2) (Cooper 2005). 
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2. Aims 
 
While molecular characterization of MSUD patients is essential to provide carrier testing 
for at-risk relatives and pre-natal diagnosis for high-risk pregnancies, it might also be important 
for a proper disease management. On the other hand, understanding the pathobiology of 
mutations is fundamental to strengthen the relationship between molecular defect and disease. 
 Acknowledging that, the main objectives of this work were: 
1) To perform the molecular characterization of two patients recently diagnosed with MSUD 
by amplification and sequencing the entire coding and flanking intronic regions of 
BCKDHA, BCKDHB and DBT genes; 
 
2) To evaluate the putative pathogenic effect of newly identified missense mutation(s) 
through the use of available bioinformatics programs that predict the impact in the protein 
structure induced by amino acid replacements; 
 
3) To assess in silico tools to predict the effect caused by a new variation identified in intron 
1 of BCKDHA gene (c.108+6T>C) on the splicing process of the gene; 
 
4) To determine the functional impact of the substitution c.108+6T>C in BCKDHA through 
the construction of a splicing reporter minigene assay; 
 
5) In a broader perspective, it was also an objective of this work to enlarge the knowledge 
on the molecular architecture of MSUD and on the pathobiology of mutations that underlie 
the disease.  
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3. Material & Methods 
 
3.1 - Molecular characterization of MSUD patients 
 
3.1.1- Samples and DNA extraction  
 
In this study, samples from two MSUD patients whose biochemical diagnosis has been 
recently established have been analyzed to identify the disease causal mutations. Moreover, a 
sample from a Brazilian patient, for whom the molecular characterization has already been 
performed, was also studied.  
DNA was extracted from patients’ blood spot in FTA card using  the Generation Capture 
Card Kit following the protocol "Purifying DNA from difficult-to-elute dried blood spots" provided 
by the manufacturer (Qiagen).  
 
3.1.2- Amplification by PCR  
 
In order to identify the MSUD causal mutations in the patients, the entire coding and flaking 
intronic regions of the three genes most frequently associated to MSUD (BCKDHA, BCKDHB and 
DBT) were amplified by PCR using specific primers previously described in Quental et al., 2008 
(Quental et al., 2008). The PCR reaction mixtures consisted in 5 µl of MyTaq™ HS Mix (Bioline); 
1 µl of primer forward (10 mM); 1 µl of primer reverse (10 mM); 1 µl of DNA and 2 µl of H2O to 
complete a final volume of 10 µl. The amplification programs are described in table 1 whereas 
table 2 present sequences and annealing temperatures of primers used. 
Table 1.  PCR program used to amplify the entire coding and flaking intronic regions of the three genes that are most frequently 
affected in MSUD (BCKDHA, BCKDHB and DBT) 
*this information is present in table 2 and depends on the pair of primers used 
Cycling step Temperature (°C) Time Number of cycles 
Initial Denaturation 95 15 ' 1 
Denaturation 94 30 ''  
35 Annealing Variable* 1' 30''  
Extension 72 1' 
Final Extension 72 10' 1 
Hold 4 ∞ 1 
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Exons Primers names Sequences (5'- 3') Ta (ºC) 
BCKDHA 
1 1F/1R CAGAACGGGAAGAAGATGGT / CTTCGGTGTCTTCTCCAAGG 59 
2/3 116-374F/116-374R GCTTCTGATGCAGGTGGTCT / CCTCAGGTAATTCCAGCCCC 61 
4 4F/4R CCCAGCATAACCAATTGTGG / GCTGCTCCTGGAAGAACACT 59 
5 5F/5R TCCTCTTAAAACAAGCCTGAGC / TCACCAACCCAGAATTCCAC 61 
6 6F/6R CTGCTCACCACCCTCTCATC / CACAGGACACAGGACGAGAA 60 
7 7F/7R CACCCCTACCCTCCTTCCT / GTGGCTGTCAGTGCTGTGG 61 
8 8F/8R TGCCTTTATTCCGTTTCCAC / ATCACTGGGGTTATCCCTGA 59 
9 1234-1312F/1234-1312R CACAAAGGCTTGGAGTGGTT / CCCTTAGAGTGGGGCTACCT 59 
BCKDHB 
1 1BF/1BR CCCCTAAAT TTCCAGTTCCG / AATAAGCTGGGATGCAAGGA 55 
2 2-3BF/2-3BR ACTTTGACGGGTCTCCCTTT / TGTTAACCATTGAGCTCCACA 60 
3 4BF/4BR GGTAACTGTCATCCAGTGGGTAG / CTGCGGGTGGCGTTGGAAATG 61 
4 6BF/6BR TGACATTACTCTCATTTGCCACA / GGGTAGCGGCAATACTTGAA 61 
5 7BF/7BR AGGAGATTGGAAGGGAAGGA / TTCCAAGAATCCTGTTTGTTTTC* 60 
6 9BF/9BR AGCCCTTCTTAGCAGCGAGT / CACCTGAGGACAAACTAAATACCA 61 
7 10BF/10BR TGCACAAGTGTCACCTCAGA / TGAGAGCTTCCAAGCACAAC 61 
8 11BF/11BR TCAGCATTCAACTAGTTTTTGAGG / GCCAAAGGTTTCAGGGAAAT 61 
9 13BF/13BR TTTTCTACTGGGATTACAAACCA / GGAATTGCACAAGCATTGAA 61 
10 14-1BF/14-1BR CACATAATAAAACTGGGATCATG/ CGTTAATGTCAGGGGCACAT 61 
DBT 
1 DBT-1F/R GCTCGTTTCTTCCCTCCCTA / CATGCATCCCTTCACCTCTC 5*64 + 30*62 
2 DBT-2F/R GAGATAAGCCGGTATGGTTGTT / GCCCGGCTAGAAATACAGAG 5*64 + 30*62 
3 DBT-3F/R ATTTCTGCCTCTGCCTGAGA / GGATTCCCACTATCCATTAA 59 
4 DBT-4F/R TCTGAAAGTAAATGCTGGGCTA / GGGACCCAATGACAAAAAGA 58 
5 DBT-6F/R CTGAAGTTAAGTTTTACCTTGTTAC / AATTTCATTGAGCTATTTCATC 52 
6 DBT-7F/R GATACCTGATGGTTACCACATGCAT / TATGCTGACTGAAGTTGAACTTTC 53 
7 DBT-8F/R GACATTAGAGAACCTTCCATT / CAAGAGCAAAACTCTGTCTC 58 
8 DBT-9.1F/R GCGCTTTGAAATCCTCGTTA / TAATCCCAAGGAAGCAGCCT 62 
8 DBT-9.2F/R CACATGGCCTGAAGGTAACAT / GGGTAACATAATCTGCCATACAGC 5*58 + 30*56 
9/10 DBT-10/11F/R ATGGCAGTGAAGGTTGATCC / CCTACAAAAGGAGGGGAAACC 60 
11 DBT-12F/R TTGAGCTCTGAACAAGTGAAGGTT / CAGCACCATATTAAGAAGTCACAC 63 
Table 2. Sequences and annealing temperatures of primers used in amplification of entire coding and flaking intronic regions of the three genes that are most frequently affected in MSUD (BCKDHA, 
BCKDHB and DBT). 
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3.1.3- Evaluation of the success of PCR by polyacrylamide gel electrophoresis 
 
The success of the amplification reactions was tested by submitting the PCR 
products to polyacrylamide gel (T9C5) electrophoresis. The composition of the gel is 
described at the table 3. The voltage of 280V was applied during 30 minutes. The gel 
was visualized by silver staining standard protocol. 
Table 3. Composition of a polyacrylamide gel 
Component Volume 
Acrylamide solution 
(Acrylamide/Bisacrylamide 19:1 (40%)) 
3 ml 
Ammonium Persulfate (APS) 2.5% 170 µl 
Tetramethylethylenediamine (TEMED) 7 µl 
 
3.1.4- Sanger Sequencing and electropherogram analysis  
 
The amplified products were initially purified with ExoSAP-IT® (USA Products) to 
remove residues of primers and excess dNTPs not used in the PCR. For the purification 
reaction, 0.5 µl of the enzyme were mixed with 1.5 µl of amplified product and incubated 
at 37°C for 15 minutes and another 15 minutes at 85°C. Then, the sequencing reaction 
was prepared adding to each tube 2 µl of the purified PCR product, 1 µl of oligonucleotide 
primer 5’ or 3’ at 10 mM,1 µl of BigDye® Sequencing Standard Kit and 1 µl of sequencing 
buffer (Applied Biosystems). The sequencing reactions were carried out in a 2720 
Thermal Cycler (Applied Biosystems) or in a Thermal Cycler (BioRad) with the conditions 
described in the table 4.  
 
Table 4. Thermal cycler conditions for the sequencing reaction 
Cycling step Temperature (°C) Time Number of cycles 
Initial Denaturation 96 4' 1 
Denaturation 96 10 ''  
35 Annealing 55 5'' 
Extension 60 4' 
Final Extension 60 10' 1 
Hold 8 ∞ 1 
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At the end of the reaction, the sequencing products were purified in SEPHADEX® 
columns (GE Healthcare) through centrifugation for 4 minutes at 4400 rpm to remove all 
the oligonucleotide primers, dNTPs and ddNTPs that have not been used in the reaction. 
Finally, the purified products were ressuspended in 12 µl of the denaturing agent Hi-Di 
formamide and the capillary electrophoresis was performed on an ABI Prism 3130xl DNA 
Sequencer (Perkin-Elmer, Applied Biosystems).  
The electropherograms obtained were compared to reference sequences 
available in the on-line database Ensembl Genome Browser - 
http://www.ensembl.org/index.html, using Geneious 5.5.8 program. 
3.1.5- Bioinformatic analysis 
To predict the impact of novel missense alterations discarded to be 
polymorphisms the program PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) was 
used.  
In silico analysis of a likely splicing mutation was performed using the following 
bioinformatics programs: 
GenScan (http://genes.mit.edu/GENSCAN.html) (Burge and Karlin 1997) 
NNSplice: Splice Site Prediction by Neural Network (http://www.fruitfly.org/) 
MaxEnt (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) 
Human Splicing Finder (http://www.umd.be/HSF/)  
NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/).  
 
3.1.6- Protein structural analysis 
 
The E1β protein structural model with a newly identified mutation was built with 
MODELLER (Eswar et al., 2006), using the normal human sequence (PDB ID: 1X7Y) as 
template (Wynn et al., 2004). 
Generation of protein plots was performed using PyMOL (http://www.pymol.org) 
(DeLano). 
 
3.2- Functional characterization of the alteration c.108+6T>C within BCKDHA 
gene – Construction of reporter minigenes  
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The functional studies were planned for an alteration, c.108+6T>C, that was 
located in intron 1 of BCKDHA gene, lacking so any upstream 3’ splice site. It was 
needed, therefore, to produce first a rearranged exon resultant from the fusion of two 
exonic parts (one of them the BCKDHA exon 1) in order to obtain a hybrid exon 
possessing both 3´and 5´splice sites. For this reason, a hybrid splicing vector (pSPL3), 
already used in previous studies (Arrabal et al., 2011; Perez et al., 2013), that contains 
part of exon 2 of SPR gene fused to exon 1 of ALDH7A1 (Figure 8) (Pérez et al., 2013) 
was employed and modified in the present study. It was kindly provided by Bélen Pérez, 
Madrid, Spain. 
 
 
Figure 8. Representation of the pSPL3 splicing vector that contains the hybrid exon formed by part of SPR exon 2 fused 
to ALDH7A1 exon 1. Adapted from Perez et al. 2013 (Perez et al., 2013) 
 
In order to modify the vector, the region encompassing exon 1 of ALDH7A1 was 
replaced by the region of interest within BCKDHA, through a process that is described in 
detail in the next topics. 
3.2.1- Construction of intermediate minigene vector 
 
3.2.1.1- Amplification of the BCKDHA genomic DNA fragment covering the target 
region 
 
A genomic fragment of BCKDHA gene including the region where lies the 
c.108+6T>C mutation (203 bp of exon 1 and 301 bp of intron 1) was PCR amplified from 
a control DNA sample using a forward primer that includes in the 5’ side the restriction 
site (underlined) for SalI (ATATATGTCGACGTCAGATGGTGCTGGAGTTTG- named 
BCKDHA_SalI_F) and a reverse primer that includes the restriction site for EcoRV 
(TAAGCAGATATCCCTCCCCTGAATACCAGTGG – named BCKDHA_EcoRV_R_new) 
(Figure 9). Since usually restriction enzymes do not cut efficiently at sites nearby the end 
of DNA fragments, six extra nucleotides have been included as the first nucleotides in 
each primer (Cooper, 2005). The amplification reaction was performed with HotStar 
HiFidelity Polymerase Kit (Qiagen) using 10 µl of HotStar HiFidelity PCR Buffer 5X; 4 µl 
of forward and reverse primers (10 mM); 1 µl of HotStar HiFidelity DNA Polymerase; 2.5 
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µl of DNA and 28.5 µl of H2O to complete a final volume of 50 µl. The PCR conditions 
used are described in table 5.  
 
Table 5. PCR conditions used to amplify a genomic fragment of BCKDHA gene  
Cycling step Temperature (°C) Time Number of cycles 
Initial Activation 95 5' 1 
Denaturation 94 15''  
35 Annealing 64 1' 
Extension 72 1' 
Final Extension 72 10' 1 
Hold 4 ∞ 1 
 
The success of this reaction was tested through polyacrylamide gel 
electrophoresis as described in point 3.1.3, and, to confirm the integrity of the amplified 
fragment, the product was sequenced with the same primers used in the PCR and the 
conditions described in 3.1.4. 
 
 
Figure 9. Schematic representation of the fragment amplified from BCKDHA gene including the region of the c.108+6T>C 
mutation (203 bp of exon 1 and 301 bp of intron 1) using primers BCKDHA_SalI_F and BCKDHA_EcoRV_R_new.  
 
3.2.1.2- Amplification of the region of interest of pSPL3 vector 
 
The region of the pSPL3 vector that includes SPR exon 2 fused to exon 1 of 
ALDH7A1 was PCR amplified with the HotStar HiFidelity Polymerase Kit, using the same 
reaction conditions described in 3.2.1.1 but with primers pSPL3_E2E1_F  
(GGATCACCAGAATTCTGGAGC) and pSPL3_E2E1_R 
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(TCCACACAGGTACGGGATCA) (Figure 10). The conditions of this PCR are described 
at table 6.  
Table 6. PCR conditions used to amplify the region of pSPL3 vector that includes SPR exon 2 fused to exon 1 of ALDH7A1 
Cycling step Temperature (°C) Time Number of cycles 
Initial Activation 95 5' 1 
Denaturation 94 15''  
35 Annealing 61 1' 
Extension 72 1' 
Final Extension 72 10' 1 
Hold 4 ∞ 1 
 
The success of this reaction was also tested in polyacrylamide gel 
electrophoresis and the amplified product was sequenced with the primers used in the 
amplification.  
 
 
Figure 10. Representation of the fragment amplified from pSPL3 vector that includes part of exon 2 of sepiapterin 
reductase (SPR) gene fused to exon 1 of ALDH7A1 gene (Pérez et al., 2013) with primers pSPL3_E2E1_F and 
pSPL3_E2E1_R.  
 
3.2.1.3- Enzymatic restriction of DNA fragments from BCKDHA gene and pSPL3 
vector with SalI 
 
After confirming the integrity of the pSPL3 and BCKDHA fragments by Sanger 
sequencing, 21 µl of each amplicon was digested (in independent reactions) with 
restriction endonuclease SalI (Roche) using 1.5 µl of enzyme and 2.5 µl of H Buffer (final 
volume of 25 µl). The restriction sites for Sal I of the BCKDHA and pSPL3 fragments are 
schematically represented in figures 9 and 10, respectively. The reactions occurred at 
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37°C, the ideal temperature for the enzyme activity, for 2 hours and 30 minutes, and 
were performed in duplicate for both fragments. 
The products of these restrictions were separated in 2.5% agarose (ultrapure 
grade) gel electrophoresis and the fragment of pSPL3 containing SPR exon 2 and the 
fragment from BCKDHA were gel purified with Wizard® SV Gel and PCR Clean-Up 
System (Promega) following the manufacturer’s instructions. The correspondent bands 
from the duplicate reactions were eluted together in order to obtain DNA with 
concentration enough to be used in later procedures. 
The success of the enzymatic restriction reactions was confirmed by Sanger 
sequencing of the eluted DNAs using the same primers as in the PCR amplifications for 
BCKDHA fragment and with primer pSPL3_E2E1_F in the case of pSPL3; the quality of 
the DNAs was evaluated with NanoDrop ND-1000 Spectrophotometer.  
 
3.2.1.4- Ligation of SPR exon 2 to BCKDHA fragment 
 
The ligation of SPR exon 2 to the fragment from BCKDHA gene, which includes 
exon 1 and part of intron 1, was performed with Rapid DNA Dephos & Ligation Kit 
(Roche) using 4 µl of each DNA and 2 µl from DNA Dilution Buffer 5X. To this mixture it 
was added 10 µl of T4 DNA Ligation Buffer 1X and 1µl of T4 DNA Ligase. The ligation 
reaction was incubated for 60 minutes at room temperature and overnight at 4°C.  
The product of the ligation was amplified by PCR with HotStar HiFidelity 
Polymerase Kit using as primer forward primer pSPL3_E2E1_F and as primer reverse 
primer BCKDHA_EcoRV_R_new. PCR conditions used are described in table 7.  
Then, the ligation product was submitted to 1% agarose gel electrophoresis and 
the fragment with the expected size was eluted from the gel with Wizard® SV Gel and 
PCR Clean-Up System (Promega). 
The integrity of the ligation fragment amplified was evaluated by Sanger 
sequencing with primers pSPL3_E2E1_F and BCKDHA_EcoRV_R_new. The quality of 
the DNA was accessed with NanoDrop ND-1000 Spectrophotometer (Thermo scientific). 
 
 
 
 
 
 
FCUP 
Contribution to the mutational spectrum of Maple Syrup Urine Disease                                                                           
and functional characterization of the alteration c.108+6T>C in BCKDHA gene. 
53 
 
 
Table 7. PCR conditions used in the amplification of the ligation product of SPR exon 2 and BCKDHA fragment 
Cycling step Temperature (°C) Time Number of cycles 
Initial Activation 95 5' 1 
Denaturation 94 15''  
35 Annealing 64 1' 
Extension 72 1' 
Final Extension 72 20' 1 
Hold 4 ∞ 1 
 
3.2.1.5- Cloning of PCR product in TOPO TA cloning vector (pCR®2.1-TOPO®) 
 
The fresh PCR product eluted from the gel (3.2.1.4) was cloned in TOPO TA 
vector (Invitrogen) (Figure 11). The reaction mixture containing 4 µl of amplified product; 
1 µl of salt solution and 1 µl of TOPO® vector in a final volume of 6 µl, was incubated 
during 30 minutes at room temperature. 
 
  
 
 
 
 
 
 
 
 
Figure 11. Cloning of the hybrid vector (SPR-BCKDHA) in TOPO TA cloning vector. 
 
 
3.2.1.6- Transformation of One Shot® TOP 10 Chemically Competent Cells  
 
The cloning reaction was used to transform TOP10 Chemically competent cells 
(One Shot® TOP10 Chemically Competent E. coli, Invitrogen). The transformation was 
performed through the addition of 2 µl of the cloning product to a vial with 50 µl of TOP 
10 E. coli cells. This mixture was incubated on ice for 30 minutes and then heat-shocked 
for 30 seconds at 42ºC, and immediately transferred to ice during 2 minutes. Finally, 250 
µl of pre-heated S.O.C. medium were added before incubating the mixture at 37ºC with 
horizontal agitation at 200 rpm for 1 hour.  
FCUP 
Contribution to the mutational spectrum of Maple Syrup Urine Disease                                                                           
and functional characterization of the alteration c.108+6T>C in BCKDHA gene. 
54 
 
 
Different volumes of transformation product (50 µl and 100 µl) were plated on 
pre-heated LB-Agar plates with ampicillin (50 µg/ml), and incubated at 37ºC during 16-
18 hours. 
Since the TOPO vector confers antibiotic resistance, expectedly only bacteria that 
incorporate it should grow and form colonies. 
After the incubation period, several individual colonies from both plates were 
picked with a pipet tip and dipped into 20 µl of H2O. Colony PCR was then performed 
using the picked samples to identify the colonies that had incorporated the TOPO vector. 
This amplification reaction was performed with QIAGEN Multiplex PCR Kit (conditions 
referred on table 8) using TOPO specific primers M13_F (GTAAAACGACGGCCAG) and 
M13_ R (CAGGAAACAGCTATGAC). The amplicons were analyzed in polyacrylamide 
gel electrophoresis to identify putative positive colonies which are those showing a 
fragment of 906 bp. All amplified products from the suspected positive colonies have 
been sequenced (with primers M13F and R) to confirm the presence of the insert and if 
it was in the correct orientation. 
Positive colonies were maintained in culture using the remaining volume of 
solution not spent in the PCR and the pipet tip used to pick the colony and both were 
dipped into 5 ml of liquid LB medium with ampicillin (50 µg/ml) and cultured overnight at 
37°C with agitation at 200 rpm. For long term storage, a glycerol stock was prepared 
through the addition of 0.15 ml of sterile glycerol to 0.85 ml of the culture, and stored at 
- 80°C. 
 
Table 8. Colony PCR conditions used to identify positive colonies 
Cycling step Temperature (°C) Time Number of cycles 
Initial Activation 95 15' 1 
Denaturation 94 30''  
35 Annealing 54 1'30’’ 
Extension 72 1' 
Final Extension 72 1' 1 
Hold 4 ∞ 1 
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3.2.1.7- Miniprep of bacterial cultures 
 
After confirming which colonies had the intermediate minigene vector, DNA 
minipreps were prepared using the ZYMiniprep kit (NZYTech), following the 
manufacturer's instructions. 
Isolated DNAs were quantified in NanoDrop ND-1000 Spectrophotometer 
(Thermo scientific) and sequenced with primers M13F, M13R and 
BCKDHA_EcoRV_R_new to confirm that no alterations had been introduced. 
 
3.2.2- Construction of final minigene splicing vectors 
 
3.2.2.1- Digestion of pSPL3 splicing vector and intermediate minigene vector with 
BamHI and EcoRV  
 
To construct the final expression vector, both intermediate TOPO and pSPL3 
vectors were digested with BamHI and EcoRV restriction enzymes (both from Roche) 
(Figure 12). As recommended in the protocol, 3 µg of each DNA were mixed with 0.6 µl 
of BamH I; 0.6 µl of EcoR V; 3 µl of H Buffer and 15.8 µl of H2O to perform a final volume 
of 30 µl. The digestion reactions occurred at 37°C for 2 hours and 30 minutes.  
The restriction products were separated in 1% agarose gel electrophoresis and 
after conventional DNA staining, the band from pSPL3 thought to correspond to the 
vector without the “original” insert and the band assumed to be the fragment that includes 
the hybrid exon SPR-BCKDHA from TOPO, were eluted from the gel with Wizard® SV 
Gel and PCR Clean-Up System kit (Promega). The quality of the DNAs was evaluated 
with NanoDrop ND-1000 Spectrophotometer (Thermo scientific). 
To confirm the success of the digestions, Sanger sequencing was performed 
using for pSPL3 DNA the vector specific primers SD6 (TCTGAGTCACCTGGACAACC) 
and pSPL3_R (CACATGGCTTTAGGCTTTGA), while for the SPR-BCKDHA insert the 
primers were BCKDHA_EcoRV_R_new, previously used, and BCKDHA_int_seq 
(GCTCGGGGACTGGCTAGAT). 
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Figure 12. Schematic representation of construction of final minigene vector (insert of interest + pSPL3 vector). A. 
Enzymatic digestion of TOPO vector with restriction enzymes BamH I and EcoR V to extract the insert of interest (part of 
of sepiapterin reductase (SPR) gene fused to part of exon 1 and part of intron 1 of BCKDHA gene). B. Ligation of insert 
extracted from TOPO vector to pSPL3 vector after pSPL3 vector has been also digested with restriction enzymes BamH 
I and EcoR V (mentioned in 3.2.2.2)  
 
3.2.2.2- Ligation of SPR-BCKDHA fragment into pSPL3 vector 
 
To construct the final minigene vector, the hybrid exon formed by SPR exon 2 
and BCKDHA exon-intron 1 needed to be cloned in the pSPL3 vector. To that end, 150 
ng of the insert were mixed with 50 ng of pSPL3 “empty” vector; 1 µl of T4 DNA Ligase 
(5 U/µl); 2 µl of reaction buffer 10X; and H2O to obtain a total volume of 20 µl. Finally, 
the mixture was incubated at 18°C for 16 hours and at 65°C for 10 minutes.  
 
3.2.2.3- Transformation of TOP10 Chemically competent Cells with the minigene 
vector 
 
The ligation product (2.5 µl) was used to transform One Shot® TOP10 Chemically 
Competent E. coli cells (25 µl), following the protocol previously described in 3.2.1.6. 
Colony PCR at 57ºC of annealing temperature was performed to select positive 
colonies, using the pSPL3 specific primer SD6 (TCTGAGTCACCTGGACAACC) and 
primer BCKDHA_EcoRV_R (ATATATGATATCAGCCCTTCCTTCATATCCTTC), that 
anneals to the BCKDHA part of the insert .  
Positive colonies, for which, as expected, a band of 979 bp was observed in 
polyacrylamide gel, were sequenced with primers used in the PCR, to confirm integrity 
of the fragment inserted. Bacterial culture, DNA miniprep and glycerol stock have been 
performed as described in 3.2.1.6 and 3.2.1.7. 
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3.2.3- Mutagenesis 
 
The mutation c.108+6T>C in intron 1 of BCKDHA gene was introduced in the 
wild-type minigene vector by site directed mutagenesis using the QuikChange II Site-
Directed Mutagenesis Kit (Stratagene). The QuikChange Primer Design from Agilent 
Technlogies was used to design the primers sense and antisense with the mutation, 
which were: BCKDHA_MUT_108_6_C_Fw 
(GCTAGATCTGTGAGCACCTGGGCCCCAGG) and BCKDHA_MUT_108_6_C_Rv 
(CCTGGGGCCCAGGTGCTCACAGATCTAGC). 
Mutagenesis reaction was performed according to the manufacturer´s protocol 
that  briefly involves the mixture of 2.5 µl of 10X reaction buffer; 0.5 µl of dNTPs; 1.0 µl 
of each primer at 65 ng/µl; 0.75 µl of DMSO; 0.5 µl of PfuUltra High-Fidelity; 50 ng of 
template DNA and H2O to complete a final volume of 25 µl. The mixture was subjected 
to 1 minute at 95ºC, followed by 12 cycles of 50 seconds at 95ºC, 50 seconds at 58ºC, 
and 7 minutes at 68ºC. After the PCR, 0.75 µl of Dpn I was added and the mixture was 
incubated during 1 hour and 30 minutes at 37ºC. 
At the end of the procedure, 2.5 µl of the digested product was used to transform 
25 µl of XL-1 Blue supercompetent cells, as recommended by the manufacturer.  
Positive colonies were identified by colony PCR and Sanger sequencing (as 
previously described for WT minigene colonies in 3.2.2.3) to confirm the presence of the 
mutation c.108+6T>C and the absence of other alterations inadvertently introduced. 
Bacterial culture, DNA miniprep and evaluation of the quality of the DNA obtained were 
performed as previously described. 
 
 
3.3. Cell culture and transfection 
 
3.3.1- Culture and cell counting 
 
In this work, two adherent cell lines- HeLa (human cervix epithelioid carcinoma) 
and AGS (human gastric carcinoma) - were selected to be transfected with the minigene 
vectors. 
The entire procedure was performed in a laminar flow hood and all the necessary 
non-sterile material was disinfected with 70% ethanol to prevent contamination of the 
cells. 
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Cryopreserved HeLa and AGS cells were properly resuspended to be then 
maintained in culture with Dulbecco’s Modified Eagle Medium (DMEM) and Roswell Park 
Memorial Institute medium (RPMI), respectively, supplemented with 10% Fetal Bovine 
Serum (FBS) and 1% Penicillin Streptomycin (Pen Strep). The cells were maintained in 
an incubator at 37°C in a humidified atmosphere (95%) and of 5% CO2, with medium 
regularly renewed. Confluence and viability were always observed after examination with 
an inverted microscope. 
When the cell culture was confluent and showed uniform distribution in flasks, the 
culture medium was removed, cells were washed with phosphate buffered saline (PBS) 
and trypsin-EDTA was added to dissociate cells from culture flask. After 5-10 minutes at 
37°C, when the cells were already detached from the wall, they were sub-cultured by 
transferring the appropriate volume to a new flask with fresh medium.  
In order to transfect cells, a total of 4x105 cells were plated in each well of a 6-
weel plate. To determine the appropriate volume of cell suspension that should be used 
in each well, cells were counted with a Neubauer chamber (Figure 13). 
 
Figura 13. Example of a Neubauer chamber to count cells.  
 
 
To do that, a solution with 10 µl of cells suspension and 10 µl of 0.1% trypan blue, 
which also allows checking for cell viability, was prepared. Ten microliters of this mixture 
was placed in each side of the chamber (Figure 13) and the cells located in the four 
external quadrants were counted in an inverted microscope. Each square has an area 
of 1 mm2, a depth of 0.1 mm, and so, a volume of 0.1 mm3.  
The calculation of the cell concentration was determined by the following 
expression: 
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N= 
∑𝐶
4
×D ×104 cells/ml, 
 
where N is the number of cells per ml; C is the number of cells counted in each quadrant 
and D is the dilution factor which in this case was 2 (10 µl of cells suspension diluted in 
10 µl of Trypan blue). The value obtained was multiplied by 1000 to determine cell count 
in ml. 
The 6-well plate was incubated at 5% CO2, 95% humidity and 37°C. After 24h, 
the cells were at a confluence of about 70-80% and therefore suitable to be transfected. 
 
3.3.2- Transfection 
 
Three different plasmid DNAs were used to transfect both cell lines (HeLa and 
AGS), which were the empty pSPL3 vector, the WT minigene (c.108+6T) and the mutant 
minigene (c.108+6C) vector, as shown in figure 14.   
Cells were transfected with each DNA using JetPEI® transfection reagent 
following manufacturer’s instructions (POLYPLUS TRANSFECTION). Briefly, 2 µg of 
each vector DNA and 8 µl of JetPEI were independently mixed with 100 µl of 150 mM 
NaCl; the mixtures of JetPEI were then added to each DNA diluted one. Each of these 
solutions was incubated at room temperature for 30 minutes after which 200 µl of each 
was delivered to the respective well containing the cells growing in 2 ml of supplemented 
DMEM or RPMI medium (Figure 14). 
The plate was incubated at 5% CO2, 95% humidity and 37°C for approximately 
24 hours until cell recover for total RNA isolation. 
Three independent transfection experiments were performed for each plasmid 
tested to assess for reproducibility of the results. 
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Figure 14.  Representation of transfection in the 6-well plate. In A1 it is present HeLa cells transfected with empty pSPL3 
vector; in A2 it is present HeLa cells transfected with wild-type (WT) vector and in A3 it is present HeLa cells transfected 
with vector with the mutation c.108+6T>C in BCKDHA. In line B is the same but for AGS cells. 
 
3.3.3- RNA isolation 
 
Approximately twenty-four hours after transfection, the medium was removed, 
and the cells were washed with PBS and harvested by trypsinization as described above 
in 3.3.1. Then, 1 ml of DMEM supplemented medium was added to wells containing 
HeLa cells and 1 ml of RPMI supplemented medium to the ones containing AGS cells. 
The entire volume was collected into 1.5 ml tubes that were centrifuged at 1500 rpm for 
5 minutes to remove the supernatant. Finally, the cells were washed with 1 ml of PBS 
1X and centrifuged again at 1500 rpm for 5 minutes.  
RNA was extracted from the cell pellets with the High Pure RNA Isolation Kit 
(Roche), following manufacturer’s recommendations.  
The quality of all RNA samples was assessed using NanoDrop ND-1000 
Spectrophotometer (Thermo scientific). 
 
 
3.3.4- cDNA synthesis by reverse transcription 
 
The reverse transcription reactions to synthesize cDNAs were performed with the 
First Strand cDNA Synthesis Kit (Fermentas). All the components of these reactions are 
shown in table 9.  
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Table 9. Components for the reverse transcription reaction 
 
RNA 
1-1.5 µg (depending on the 
concentration of RNA 
extracted) 
Oligo (dT) primers 1 µl 
H2O To perform 11 µl 
Total volume 11 µl 
5X Reaction Buffer 4 µl 
RiboLock Rnase Inhibitor (20 u/µl) 1 µl 
10 mM dNTP Mix 2 µl 
RevertAid-M-MuLV Reverse Transcriptase (200 u/µl) 2 µl 
Total volume 20 µl 
 
The mixtures were subsequently incubated at 37°C for 60 minutes followed by 5 
minutes at 70°C. Control reactions were also prepared, namely a reverse transcriptase 
negative control to assess for genomic DNA contamination of the RNA samples, which 
contained every reagent used except the RT enzyme, and a template negative control 
that contained every reagent except RNA template, allowing to control for reagents 
contamination.  
  
3.3.5- Transcript analysis 
 
Subsequently to cDNA synthesis, the samples were directly used in PCR 
reactions using pSPL3 vector specific primers (SD6 and SA2). For the amplification 
reaction, a final volume of 50 µl was used including 25 µl of 2x QIAGEN Multiplex PCR 
master mix (Qiagen); 5 µl of each primer (2 µM); 5 µl of cDNA template and 10 µl of H2O. 
The PCR conditions are described in table 10. 
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Table 10. PCR conditions reaction for amplification of cDNA samples 
 
The products of the amplification were run in 2% agarose gel electrophoresis, in 
order to compare the transcripts resultant from the WT and the mutant minigenes. The 
stained bands in the gel were eluted using the Wizard® SV Gel and PCR Clean-Up 
System (Promega) and sequenced with primers SA2, SD6 and BCKDHA_int_seq. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cycling step Temperature (°C) Time Number of cycles 
Initial Denaturation 95 15 ' 1 
Denaturation 94 30 ''  
35 Annealing 60 1' 30'' 
Extension 72 1' 
Final Extension 72 10' 1 
Hold 4 ∞ 1 
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4. Results and discussion  
4.1. Molecular characterization of MSUD patients 
In this study the molecular characterization of two MSUD patients has been 
successfully achieved. In both patients the entire coding and flaking intronic regions of 
BCKDHA, BCKDHB and DBT genes were screened to search for the causing mutations 
of the disease. A third patient (patient 3) was also studied to functionally confirm the 
pathogenic effect of a substitution previously identified. 
Although the BCKD complex, whose enzymatic activity is disrupted in MSUD 
patients, is composed for more subunits other than the ones encoded by the above 
mentioned genes, namely the regulatory kinase and phosphatase, experience to date 
shows that the majority of the disease causal mutations affects one of the three catalytic 
components specific of BCKD, as it was also corroborated by the results here obtained. 
 
4.1.1. Patient 1 
Patient 1, of Angolan origin, presented the usual symptoms of MSUD in the first 
days of life and the clinical diagnosis was then confirmed. No detailed description of the 
biochemical characterization and clinical presentation of this patient was available, 
being, however, known that at the time of the diagnosis he presented with a severe 
MSUD phenotype. 
Sequence analysis revealed the presence of an 11-bp deletion in homozygosity 
in the BCKDHB gene (c.93_103del11) (Figure 15), leading to an alteration of the reading 
frame starting at residue 32, in which an alanine is replaced by a phenylalanine, and to 
the insertion of a stop codon 48 residues downstream (p.Ala32Phefs*48). This deletion 
occurs in exon 1 of the gene, in a region encoding the mitochondrial targeting leader 
peptide. 
The patient here studied manifested the most severe form of the disease which 
is in accordance with the serious effect caused by the mutation he carries. The alteration 
leads to the complete loss of function of the E1β protein and to the consequent 
degradation of E1α because both subunits cannot assemble to form a stable E1 tetramer.  
It has been suggested that deletions occurring in repetitive genomic regions might often 
arise due to slipped mispairing or unequal chromosome crossing-over event (Nobukuni 
et al., 1991).  Since the deletion here identified occurs in a repetitive region and in 
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addition a duplication of the same 11bp sequence was previously identified as a cause 
of MSUD (Rodriguez-Pombo et al., 2006), it appears that region in the BCKDHB gene is 
indeed prone to deletion events, which probably result from one of the referred 
mechanisms. 
Of note that this alteration was firstly reported in 1991 by Nobukuni and 
collaborators in Japanese patients and, since then, it was also identified in MSUD 
individuals from other origins such as Italian, Spanish, Lebanese and now, in this study, 
Angolan, (Nobukuni et al., 1991) (Parrella et al., 1994) (Rodriguez-Pombo et al., 2006) 
(Tabbouche et al., 2014). Given the worldwide distribution of c.93_103del11 it would be 
interesting to perform haplotypic analyses to clarify whether it arose recurrently in 
different regions, which would pinpoint, if confirmed, the presence of a mutational hot-
spot in exon 1 of BCKDHB gene.       
 
Figure 15. Representation of the 11 bp deletion in BCKDHB gene that causes MSUD in patient 1 in comparison with a 
reference sequence. A. Reference sequence. B. Sequence of BCKDHB gene from patient 1, in which the deletion 
c.93_103del can be observed. 
 
4.1.2. Patient 2 
 
Patient 2, of Portuguese origin, was identified as a suspect MSUD case in the 
newborn screening program. The clinical diagnosis made at the initial days of life was 
further biochemically confirmed (detailed data not available). 
At the molecular level, the patient was found to be a compound heterozygous for 
two mutations also located in BCKDHB gene. One of them is a nonsense substitution in 
exon 7 of the gene, c.799C>T; p.Gln267Ter (Figure 16).  This alteration had already 
been described in patients from different origins (Bentley et al., 2008) but it seems to be 
particularly common in the Iberian Peninsula. In the study of Rodriguez-Pombo et al. 
(Rodriguez-Pombo et al., 2006), in which 33 Spanish patients were studied, the mutation 
p.Gln267Ter, occurred in 3 of the 30 BCKDHB mutated chromosomes, having been also 
reported as one of the most frequent mutations in BCKDHB gene in Portuguese patients 
(Quental et al., 2008).  
A 
B 
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All of the patients carrying the alteration presented with the classic MSUD form, 
a phenotype which is understandable given the predicted effect of the mutation in 
impairing complex formation due to the induced E1α and E1β instability that leads to 
consequent degradation of the committed complex (A et al., 2000).  
 
Figure 16. Representation of mutation c.799C>T in BCKDHB gene in comparison to a reference DNA. A. Sequence of 
from patient 2, were the mutation c.799C>T is present. B. Reference sequence. 
 
Besides p.Gln267Ter, one novel missense alteration also in the BCKDHB gene 
was identified in this patient: c.359T>C, which results in the amino acid change 
p.Phe120Ser (Figure 17).  
 
 
Figure 17. Representation of the mutation c.359T>C in BCKDHB gene in comparison to a reference sequence. A. 
Sequence from patient 2, were the mutation c.359T>C in present. B. Reference sequence. 
 
Since this alteration was still neither described nor listed as a polymorphism in 
available databases like Ensembl Genome Browser 
(http://www.ensembl.org/index.html), several analyses were conducted to assess its 
putative pathogenic effect.  
Firstly, PolyPhen-2 was used, a software tool that predicts the possible impact of 
an amino acid substitution on the structure and function of a human protein using 
physical/structural and comparative/evolutionary considerations (Adzhubei et al., 2010). 
The predictions of the program discriminate substitutions that are probably damaging; 
possibly damaging or benign according to scores evaluated as 0 (most probably benign) 
to 1 (most probably damaging).  
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According to PolyPhen-2, the alteration p.Phe120Ser was functionally damaging 
for the protein with a score of 1, which corresponds to the highest probability of a 
substitution be damaging (Figure 18).  
 
 
 
 
Figure 18. Prediction made by PolyPhen-2 program. It is predicted that the mutation in the Phe120-β residue, 
p.Phe120Ser, is functionally damaging with a score of 1. 
 
Next, the mutation was analysed with Site Directed Mutator (SDM), which is a 
method developed to predict changes in the stability of proteins caused by mutations 
(Topham, Srinivasan et al., 1997). SDM calculates a stability score that is analogous to 
the free energy difference between a wild-type and mutant protein. The stability score is 
useful for predicting whether a mutation will impact protein structure, having so a role in 
disease.  
SDM uses the local structural environment of the wild-type and mutant residues 
to calculate the stability score. This score (Pseudo DELTA DELTA G) can be negative, 
pointing to a destabilizing mutation, or positive, indicating that the mutation is stabilizing. 
The result obtained using SDM to test the effect of the replacement of phenylalanine by 
a serine at position 120 of E1β protein (Figure 19), showed a Pseudo DELTA DELTA G 
of -2.74 for the referred mutation. This score means that this substitution is very probably 
highly destabilizing, causing protein malfunction and disease. 
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SDM RESULTS: 
Wild-type residue: F 
Residue position in wild-type pdb file: 70 
Mutant residue: S 
Local structural environment of wild-type residue 
Secondary structure = extended strand 
Solvent accessibility = 26.6% (partially accessible) 
Sidechain hydrogen bond satisfaction = NO_HBONDS 
Local structural environment of mutant residue 
Secondary structure = extended strand 
Solvent accessibility = 47.5% (partially accessible) 
Sidechain hydrogen bond satisfaction = NO_HBONDS 
Pseudo DELTA DELTA G = -2.74 
This mutation is predicted to be highly destabilizing and cause protein malfunction and disease. 
Figure 19. Predicted effect of the mutation p.Phe120Ser in E1β protein.  
To gain insights into the specific structural alterations induced by the referred 
amino acid replacement, the structure of E1β subunit with the serine residue at position 
120 was constructed and compared with the normal one, that is, instead with 
phenylalanine.  
This substitution is located at strand c in the interior of β subunit, which therefore 
does not seem to affect the interaction with E1α (Figure 20). However, the detailed 
structural analysis of both E1β proteins (normal and with the mutation) (Figure 21A and 
B, respectively) revealed that the replacement indeed causes a conformational 
alteration, because the interactions that residue Arg111 of helix 2 establishes with 
Lys116, positioned in the loop between helix 2 and strand c, and Val119 from strand c, 
were no longer observed. The side chains of the mentioned residues are positioned 
differently as a consequence of the Phe120Ser substitution, preventing these two 
interactions to be established (Figure 21). It is therefore predictable that the stability of 
the region involving helix 2, strand c (where the mutation is present) and the loop that 
exists between these two structures, will be destabilized ultimately affecting BCKD 
complex activity. 
Interestingly, it was before reported the alteration Val119-β, involving the residue 
immediately upstream of the altered residue here identified (Chuang et al., 2004). In the 
case of Val119-β, the replacement of valine by glycine was predicted to lead to the 
misfolding of the β subunit. The proximity of the two mutations seems to strength the 
evidence that the alteration newly identified in this study is the causal mutation 
responsible for the MSUD phenotype in patient 2. 
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Figure 20. Structural representation of E1 heterotetramer: E1α (purple); E1β gray); E1α′(blue) and E1β′ (yellow). The 
phenylalanine residue that undergoes the alteration is represented in orange.  
 
Figure 21. Structural representation of part of E1 β subunit of BCKD complex A. Structural representation of normal E1 
β protein (120Phe) in which it is possible to observe the interactions that Arg111 located in helix 2, establishes with 
Lys116, positioned in the loop between helix 2 and strand c, and Val119, situated in strand c. B. Structural representation 
of mutant E1 β protein (120Ser) in which the referred two interactions are no longer established. 
4.1.3. Patient 3 
The molecular characterization of patient 3, a Brazilian child, had already been 
performed in our group (data not published). The unique alteration identified in the patient 
after sequencing BCKDHA, BCKDHB and DBT genes was a mutation in intron 1 of 
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BCKDHA, involving a substitution of a thymine by a cytosine at position +6 (c.108+6T>C) 
(Figure 22). Given that this alteration had never been described before, it was quite 
challenging to ascertain its molecular consequences and pathogenicity, which explains 
having elected the issue as one of the main objectives of this study. An in silico splicing 
analysis was initially conducted and then a splicing reporter minigene system was 
implemented. These results for the functional characterization of the alteration 
c.108+6T>C are described in detail in the next point. 
 
  
 
 
 
 
Figure 22. Representation of the mutation c.108+6T>C in intron 1 of BCKDHA gene. The substitution in highlighted in 
blue. 
 
The variations identified in the above mentioned patients are described in table 
11. 
 
Table 11. Variations identified in BCKDHA and BCKDHB genes 
Patient Gene Exon/Intron Nucleotide change Protein 
prediction 
Reference 
1 BCKDHB Exon 1 c.93_103del p.Ala32Phefs*48 (Nobukuni, 
Mitsubuchi et al. 
1991) 
2 BCKDHB Exon 4 c.359T>C p.Phe120Ser This study 
2 BCKDHB Exon 7 c.799C>T p.Gln267Ter (Nellis et al., 
2003) 
3 BCKDHA Intron 1 c.108+6T>C Skipping of exon 
1* 
This study 
DNA mutation numbering is based on cDNA reference sequence (GenBank Accession number NM_ 000709 for BCKDHA 
gene and NM_ 000056  for BCKDHB gene) considering nucleotide +1 as the A of the ATG translation initiation codon.  
* Results predicted in this study and present in the next topics of Results and Discussion section. 
 
 
4.2. Functional characterization of the alteration c.108+6T>C within BCKDHA gene 
The demonstration of the pathogenic impact of an intronic alteration especially 
when it is not located in the most conserved dinucleotides at each end of the intron, is 
usually not easy being even more difficult when RNA sample from the carrier individual(s) 
is not available, as occurs in the case of patient 3 presented in this study. 
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However, the combination of in silico predictions provided by bioinformatics 
programs with artificial systems using exon-trapping vectors, can afford valuable 
evidence to elucidate the effect of substitutions in mRNA splicing. Both approaches were 
here implemented to assess the pathogenicity of c.108+6T>C in BCKDHA, as will be 
presented in detail in the next topics. 
4.2.1. In silico splicing analysis 
Five bioinformatics tools were used to evaluate the potential impact of the newly 
identified mutation c.108+6T>C located in intron 1 of BCKDHA gene. Their predictions 
are hereafter described.  
 
4.2.1.1. GENSCAN (http://genes.mit.edu/GENSCAN.html) 
 
GENSCAN is a bioinformatic program which identifies complete exon/intron 
structures of genes in genomic DNA. This program is also able to predict multiple genes 
in a sequence, to deal with partial as well as complete genes and to predict consistent 
sets of genes occurring on either or both DNA strands (Burge and Karlin, 1997).   
In this study, GENSCAN was used giving as input files part of the genomic 
sequence of BCKDHA gene, either the normal sequence or the mutant one, including 
exon 1 and flanking non-coding regions since c.108+6T>C is located in intron 1. In this 
way, can be compared the predictions and associated scores on exon 1 given for both 
sequences. 
 
 
 
Figure 23. Predicted exon with GENSCAN program, analyzing the normal sequence. The length of predicted exon and 
the score are surrounded by a red circle.  
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Figure 24. Predicted exon with GENSCAN program, analyzing the sequence with mutation c.108+6T>C. The length of 
predicted exon and the score are surrounded by a red circle. 
 
Concerning the normal sequence, the program predicted, with the high score of 
0.792, the presence of exon 1 in BCKDHA encompassing a coding region of 108bp in 
size (Figure 23), which was correct since the prediction matched the annotated BCKDHA 
sequence. When the sequence with the mutation was used, the program also predicted 
an exon with the same length, but the yielded probability decreased to 0.516 (Figure 24). 
This “P” value provides an indication of the likelihood that a predicted exon is correct. 
Although these results raised the suggestion that c.108+6T>C might influence 
the normal splicing pattern, since splicing of exon 1 was not predicted with the same 
level of certainty in the mutated and normal sequences, they were not clear enough to 
draw confident conclusions on the effect of this substitution. 
 
 
4.2.1.2. Splice Site Prediction by Neural Network (NNSplice) 
 
Another bioinformatics resource used was NNSplice 
(http://www.fruitfly.org/seq_tools/splice.html/), which is a program that leads to splice site 
predictions for human and Drosophila melanogaster by training and testing sets of splice 
sites that are available in the BDGP (Berkeley Drosophila Genome Drosophila Genome 
Project) and from the collection of representative and standardized data sets of human 
and D. melanogaster genes. The Splice Site Prediction by Neural Network is a prediction 
method for donor and acceptor splice sites based on neural networks (Reese et al., 
1997). 
The prediction that NNSplice produced for the normal sequence of BCKDHA was 
a wild-type 5´ splice site with a score of 0.66. Importantly, giving as input file the mutant 
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sequence this splice site was no longer identified (cutoff 0.40), indicating that the mutant 
5’ splice site is probably not used. 
 
4.2.1.3. MaxEntScan   
 
 
MaxEntScan software uses a method based on the 'Maximum Entropy Principle' 
to score 5’ and 3´splice sites - 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html) (Yeo and Burge, 
2004). The higher the score, the higher the probability that the sequence is a true splice 
site, with ideal scores of 11,81 and 13,59 for 5´and 3´splice sites, respectively (Eng et 
al., 2004). The utility and accuracy of MaxEntScan was clearly evidenced in the study of 
Eng, Coutinho et al., 2004, which involved the prediction of splicing mutations in the ATM 
gene (Eng et al., 2004). 
 
 
Figure 25. Prediction of maximum entropy with normal sequence 
 
 
 
 
 
Figure 26. Prediction of maximum entropy with sequence with mutation c.108+6T>C 
 
 
Comparing the predictions of MaxEntScan obtained with the normal sequence 
(Figure 25) and the mutant one (Figure 26), an overt difference emerged between the 
score of the 5´splice produced with the normal sequence, 7.00, which decreases to 3.27 
with the mutated one. Once again, this result indicates that the mutation might probably 
affect the recognition of the 5’ motif by the spliceosome and consequently affect the 
normal splicing pattern of the gene. 
 
4.2.1.4. Human Splicing Finder  
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Human splicing finder 2.4.1 (HSF) - (http://www.umd.be/HSF/) - is a tool to predict 
the effects of mutations on splicing signals or to identify splicing motifs in any human 
sequence (Desmet et al., 2009).  
Concerning the sequences under study, HSF produced the matrices shown in 
figure 27, which reveal that the wild-type 5´splice site was identified with a score of 81.24, 
while the mutant one had a slightly lower value (79.07). Although this might appear a 
minor alteration, the program considers as strong sites those presenting consensus 
values higher than 80 and as less strong sites those with score values ranging between 
70 and 80. 
 
Figure 27. Potential splice sites predicted by BDGP program  
 
 
4.2.1.5. NetGene2  
 
NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/) is another tool that 
predicts coding region splice sites (Hebsgaard et al., 1996). In the case of the BCKDHA 
sequences, the program has identified the natural splice site in the WT sequence with a 
confidence of 0.41, while this splice site was no longer identified in the mutated 
sequence.  This result favors again the potential pathogenic effect of the alteration 
c.108+6T>C, indicating that the mutant 5´splice site is not recognized by the splicing 
machinery. 
 
FCUP 
Contribution to the mutational spectrum of Maple Syrup Urine Disease                                                                           
and functional characterization of the alteration c.108+6T>C in BCKDHA gene. 
74 
 
 
4.2.2. Cloning and construction of reporter minigenes 
The splicing alteration identified in patient 3 is located in intron 1 of BCKDHA gene, 
a location that raises technical concerns that needed to be overcome viewing the 
construction of the minigene. Since the first and last exons of a gene lack either the 3´ss 
or the 5´ss, respectively, it is necessary to construct a rearranged exon that results from 
the fusion of two exonic parts in such a way that the resulting hybrid exon contains both 
a 3’ and a 5’ss (Berget, 1995) (Gaildrat et al., 2010).  
This strategy has been used successfully in several studies from Belén Pérez group 
in Madrid, who kindly provided the hybrid pSPL3 vector to be used in this study (Arrabal 
et al., 2011); (Perez et al., 2013). 
In the work of Arrabal and collaborators (Arrabal et al., 2011) a hybrid exon containing 
part of exon 2 (with its 3’ ss) fused with exon 1 (with its 5’ ss) of SPR gene was 
constructed to study the impact of a mutation located in the last nucleotide of exon 1. 
More recently, the same hybrid minigene was successfully used and modified to study a 
mutation in the first exon of ALDH7A1 (Perez et al., 2013). Given that both studies 
demonstrated the utility and applicability of the minigene splicing assays to determine 
the pathogenic impact of nucleotide alterations located in the first exon/intron boundary 
that might impair the normal splicing pattern of a gene, the strategy was implemented in 
the present study. 
To functionally study the mutation c.108+6T>C in BCKDHA gene, our initial approach 
was to use the minigene sent from Spain (Figure 28) and replace the fragment 
correspondent to ALDH7A1 by the fragment of interest amplified from BCKDHA gene, 
maintaining the SPR region with its 3´ss. However, the restriction enzyme SalI that 
needed to be used in this process cuted the pSPL3 vector in two sites, instead of only 
one as initially expected, therefore impairing the remaining procedure.  
To overcome this problem we decided first to construct an intermediate reporter 
minigene using TOPO vector and then the final splicing minigene vector. These results 
are presented and discussed below. 
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Figure 28. Representation of the pSPL3 splicing vector that contains the hybrid exon formed by part of SPR exon 2 fused 
to ALDH7A1 exon 1 which was used as final minigene by Perez et al. (Perez et al., 2013). 
 
4.2.2.1. Construction of an intermediate minigene vector  
 
To construct the intermediate minigene, the region of interest from BCKDHA 
including 203 bp of exon 1 and 301 bp of intron 1, where the mutation is located, was 
amplified from genomic DNA of a control individual. The region of pSPL3 vector that 
includes SPR fused to ALDH7A1 was also PCR amplified. As is possible to observe in 
figure 29, both amplification reactions were successful since strongly stained DNA 
fragments with the expected sizes were visualized on the agarose gel.  
 
Figure 29. Agarose Gel Electrophoresis of PCR Products A. Ladder of 100 bp. B. PCR product of fragment from BCKDHA 
gene (530 bp; the size of the fragment is longer than 504bp because of the extra bases included in both primers). C. 
negative control of PCR reaction of fragment from BCKDHA gene. D. PCR product of fragment from pSPL3 vector (594 
bp). E. negative control of PCR from fragment of pSPL3 vector. 
 
Both DNA fragments were subsequently digested with SalI enzyme and ligated 
to construct a hybrid exon formed by SPR exon 2 and BCKDHA exon 1 – intron 1. This 
ligation product was then PCR amplified and the efficiency of the reaction was assessed 
by 1% agarose gel electrophoresis, in which was possible to observe a band of the 
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expected size (803 bp) (Figure 30). The band was further eluted from the gel and 
sequenced (Figure 31).  
 
 
 
Figure 30. A. Ladder of 1000 bp. B. PCR product of the ligation of SPR and BCKDHA fragments after digestion with 
restriction enzyme SalI. C. Negative control from PCR reaction  
 
 
 
Figure 31. Representation of the ligation between exon 2 from SPR gene and exon 1 and part of intron 1 from 
BCKDHA gene A. Reference sequence created in Geneious program. B. Electropherogram of the fragment corresponding 
to ligation between SPR and BCKDHA fragments 
 
This amplified hybrid exon – SPR+BCKDHA – was then cloned into pCR®2.1-
TOPO vector, and used to transform TOP10 chemically competent E. coli. Colony PCR 
was implemented to select colonies that integrated the plasmid with the fragment of 
interest,  and the resultant products were then tested in a polyacrylamide gel (Figure 32), 
in which it was possible to observe that only one colony showed a fragment that could 
potentially be the one of interest (906 bp). This PCR product was sequenced, which 
permitted to confirm that it was indeed the expected fragment inserted in the correct 
orientation. 
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Figure 32. Colony PCR from some of the colonies that grew after the transformation of TOP10 competent cells with TOPO 
vector with the insert of interest. The colony indicated with the arrow represents the one that has approximately the 
expected (with 906 bp; PCR performed with TOPO specific primers M13 F and R). 
 
Only one colony had incorporated the insert. This positive colony was maintained 
in culture using the remaining volume of solution not used in the PCR, while the pipet tip 
used to pick the colony was dipped into 5 ml of liquid LB medium with ampicillin (50 
µg/ml), and was cultured overnight at 37°C to produce numerous copies of intermediate 
vector. 
At the end of this step, the intermediate vector was successfully constructed. 
 
 
4.2.2.2. Construction of final minigene splicing vector 
 
After the construction of the intermediate minigene vector, created with the purpose 
of producing numerous copies of the inserted fragment, the final minigene vector was 
constructed with pSPL3 vector, which was designed to express the protein product 
coded by the inserted gene. 
To construct the final reporter minigene, the intermediate vector that includes the 
hybrid exon SPR-BCKDHA was digested with restriction enzymes BamHI and EcoRV as 
well as the pSLP3 minigene vector sent from Spain (that includes the hybrid SPR-
ALDH7A1 insert). The products of both digestions were separated by agarose gel 
electrophoresis and the target fragments were cut from de gel to subsequently elute the 
DNA.  
As can be seen in figure 33, the enzymatic restrictions were well succeed since 
the distinct fragment were clearly separated from each other and all had the expected 
sizes. The fragments of interest for the ligation were eluted from the agarose gel, reason 
that explain not being present in the picture shown in figure 33. These fragments 
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corresponded to the pSPL3 vector without the “original” insert and to the fragment that 
includes the hybrid exon SPR-BCKDHA, which was ligated to the pSPL3. Once again, 
the ligation product was used to transform TOP10 competent cells but only one colony 
grew. Colony PCR from that unique colony was performed to assess the presence and 
integrity of the insert, which was indeed confirmed since the band of expected size in the 
agarose gel was eluted and submitted to Sanger sequencing that revealed the presence 
of the fragment. Finally, DNA was isolated from the culture of that colony and the wild-
type/control minigene was successfully constructed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. A. Ladder of 100 bp .B. Product of enzymatic restriction of pSPL3 vector provided by Belén Pérez with BamHI 
and EcoRV resulting in a fragment of 5503 bp that correspond to pSPL3 vector without the “original” insert and in a 
fragment of “original” insert with 528 bp. The band correspondent to pSPL3 vector without the insert was already eluted 
from the gel when the picture was captured. C. Product of enzymatic restriction of intermediate minigene. The results of 
this reaction are a fragment correspondent to TOPO vector without the insert and the other fragment correspond to the 
hybrid exon SPR-BCKDHA (751 bp) which was excised from the gel.  
 
4.2.2.3. Mutagenesis 
 
As the DNA sample from the Brazilian patient with the mutation c.108+6T>C had not 
sufficient quality to be used in the minigene construction, we decided to insert the 
mutation in the previously constructed wild-type reporter splicing minigene, through site-
directed mutagenesis. The mutant minigene was successfully constructed since the 
mutation c.108+6C was introduced and no more alterations were inserted. 
In figure 34, it is possible to compare part of the WT minigene sequence with the 
mutant one.  
A            B            C 
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Figure 34. Comparison of the WT sequence with the sequence with the mutation c.108+6T>C to verify the success of the 
mutagenesis reaction. The red arrow indicates where the mutation was inserted. A. WT sequence B. sequence with 
mutation c.108+6T>C.  
 
 
 
4.2.2.4. Transfection and cDNA analysis 
 
After obtaining the final minigene with the WT sequence and the minigene with the 
alteration c.108+6T>C (Figure 35.A), transfection in HeLa and AGS cells was performed 
with each of these minigenes and, as a control assay, a minigene with the empty vector. 
These cell lines were selected because they are easy to maintain and transfect, and the 
comparison of the results obtained in both of them could be useful if ambiguous results 
were observed (Cooper, 2005). The purpose of these transfections was to verify if the 
presence of the referred substitution had any effect on mRNA splicing.  
After transfection, RNA was extracted from both cell lines, cDNA synthesized, and 
PCR performed using vector specific primers to amplify transcripts produced in each 
experiment. Three independent assays were performed reproducing the same 
conditions to strengthen the quality of results. In all of them, the transcripts produced 
were concordant as showed the electrophoretic run on 1.6% agarose gels (Figure 35.B).  
In the case of the empty pSPL3 used as a control, the size of the band fitted the 
expectations for an empty vector, which was further confirmed by Sanger sequencing. 
Regarding the WT minigene, two transcripts were produced, both of them resulting 
from correct splicing leading to inclusion of the hybrid exon SPR-BCKDHA. The smallest 
transcript corresponds to fragments in which the splicing occurred at a cryptic 3’ splice 
site within the exonic sequence as previously described by Arrabal and collaborators 
who have also used a hybrid minigene with SPR exon 2. Once again, the integrity of both 
transcripts was confirmed by Sanger sequencing. 
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Figure 35. Minigene analysis of the alteration c.108+6T>C. A. Schematic drawing of the hybrid exon with the mutation 
c.108+6T>C cloned in pSPL3 vector with the corresponding sequence analysis. B. Post transfection PCR products of the 
minigene constructs obtained by SD6 and SA2 primers. L. Ladder of 100 bp. pSPL3 ø. Empty vector. WT. WT minigene. 
MUT. Mutant minigene.   
 
In the case of mutant minigene, the transcriptional pattern detected was different 
from that of the WT (figure 35.B). The major transcript corresponded to the empty vector 
resulting from splicing between vector sequences, which means that the entire hybrid 
exon inserted in pSPL3 was skipped. This result indicates that splicing was made with 
the canonical splice sites of the vector, being therefore plausible to conclude that the 
substitution c.108+6T>C might cause exon 1 skipping, confirming the suspected disease 
causative effect of the mutation. 
Sequence between -2 and +6 of the splice-donor site are commonly highly 
conserved (Mount, 1982) and most known mutations involving these sites affect 
seriously the correct splicing. Although splicing mutations at positions +6 are not very 
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frequent, some reports already exist describing mutations in similar position to the one 
where c.108+6T>C lies (+6T>C). For instance, c.313+6T>C in LDLR gene, which is 
associated to familial hypercholesterolaemia (Bourbon et al., 2009), and IVS7+6T>C in 
ABCA I gene that causes low HDL-C (Rhyne et al., 2009). Interestingly, both these 
mutations cause exon skipping, which to a certain extent mirror our results. 
The longer transcript observed in the mutant minigene corresponds to the entire 
sequence contained in the fragment amplified with vector specific primers, and therefore 
includes the whole insert introduced in the vector (exon 2 from SPR gene, exon 1 and 
part of intron 1 from BCKDHA gene). Probably, this transcript results from a technical 
artifact of the minigene assay, a secondary result that is known to occur often.  
All data here presented clearly indicate that the mutation c.108+6T>C in intron 1 
of BCKDHA gene impairs the recognition of the 5’ splice site by the splicing machinery, 
being very likely a MSUD causal mutation.  
However, because fragments able to be inserted in minigene are of limited size, 
it was not possible to include the entire BCKDHA intron 1 (it has more than 12Kb), and 
so it cannot be excluded the possibility that a cryptic splice site in the remaining part of 
intron 1 is used instead of the normal one. Only the analysis of patient´s RNA sample 
could unequivocally elucidate this uncertainty and clearly elucidate the impact of the 
mutation.  
Nevertheless, as demonstrated in previous studies, the exon-trapping system is 
a reliable tool that allows to have a prediction of whether a substitution of unknown 
significance influences splicing in vivo, although it is not always possible to fully 
understand the level of impairment caused.  
Despite the limitation, this study affords strong evidence on the pathogenic effect 
of the alteration c.108+6T>C in homozygosity in BCKDHA gene, being very probably the 
cause of MSUD in patient 3. 
Toward that conclusion pointed the results from the bioinformatics analyses 
undertaken, since all tools indicated a potential alteration in the recognition of the 5’ 
splice site where the substitution is located. Of note the predictions of the programs 
NNSplice and NetGene2, both indicating that the mutant splice site ceased to be 
recognized by the splicing machinery, which afterwards was validated by the functional 
assays performed. 
In relation to the molecular spectrum of MSUD, up to now only few splicing 
alterations have been described, four in BCKDHA. Possibly this number corresponds to 
an underestimate since the screening of intronic regions is not always done when 
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searching for MSUD causative mutations. This study also illustrates how useful can be 
the investment in a fine molecular characterization of MSUD patients.    
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5. Conclusion 
 
This project focused on the molecular characterization of three MSUD patients.  
For two of them, the characterization was completely performed in this study, 
while for the remaining patient it was possible to demonstrate through functional assays 
the effect of the alteration identified in a previous study. 
A total of three mutations were found in BCKDHB gene, two of them already 
known as a cause of MSUD: a deletion of 11 bp (c.93_103del11; p.Ala32Phefs*48) 
detected in homozygosity in one of the patients, and a nonsense mutation known to be 
particularly frequent in the Iberia Peninsula, c.799C>T (p.Gln267Ter), identified in 
heterozygosity in another patient. The third alteration, also detected in heterozygosity, 
was a missense substitution, c.359T>C (p.Phe120Ser). Since the p.Phe120Ser mutation 
had never been described before and was not classified as a polymorphism in on-line 
databases, to infer its putative pathogenic impact several bioinformatics programs were 
used and a 3D structural analysis was performed, with results consistently indicating the 
disease causative effect of the mutation. 
Considering the third patient, the previous screening of the genes most frequently 
affected in MSUD lead to the detection of a new alteration in homozygousity, located in 
intron 1 of BCKDHA gene (c.108+6T>C). Given that this substitution was not located in 
the almost invariant dinucleotides at intron ends, for which pathogenicity is the 
commonest consequence, and since no RNA sample from the patient was available, 
alternative tools have been implemented to determine its effect. Specifically, very 
detailed bioinformatics analyses were conducted to evaluate the impact of the 
substitution in the recognition of the 5’ splice site by the splicing machinery. In addition, 
a minigene assay was also implemented to evaluate the effects at the mRNA level, once 
is now widely acknowledged that minigene assays represent an extremely useful and 
reliable tool to access the impact of substitutions of unknown clinical significance on 
splicing, with  results showing an excellent correlation with those obtained in RNA from 
cell cultures of patients ((Fernandez-Guerra, Navarrete et al. 2010); (Arrabal, Teresa et 
al. 2011); (Perez, Gutierrez-Solana et al. 2013)).  
The functional characterization of the mutation c.108+6T>C in BCKDHA gene 
here performed involved the successful construction of two hybrid minigenes that 
contained the exon 1 and part of intron 1 from BCKDHA gene with the normal or mutant 
nucleotide. After transfection in two different cell lines (HeLA and AGS), subsequent RNA 
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isolation and cDNA synthesis were performed to analyze the transcripts produced by 
both minigenes. The approach clearly indicated that the alteration c.108+6T>C is 
pathogenic, probably leading to the skipping of exon 1 of BCKDHA gene, a result that 
otherwise was concordant with the indications provided by the bioinformatics analyses, 
especially those relying on the NNSplice and NetGene2 programs since both have 
predicted that the affected 5’ splice site was no longer recognized. 
Despite the strong evidence obtained pointing to c.108+6T>C as a MSUD causal 
mutation, since it was not technically possible to include the entire BCKDHA intron 1 (it 
has more than 12 Kb) in the minigene, a cautionary uncertainty persists on whether the 
skipping of the exon1 is the direct consequence of the alteration. If only the analysis of 
patient´s RNA sample could unequivocally elucidate this doubt, in this study important 
steps were taken to   understand the impact of this mutations.  
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